{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:17:04Z","timestamp":1780373824842,"version":"3.54.1"},"reference-count":54,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1517\/14656566.5.5.1175","type":"journal-article","created":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T02:04:07Z","timestamp":1115258647000},"page":"1175-1186","source":"Crossref","is-referenced-by-count":39,"title":["Etanercept: a clinical review of current and emerging indications"],"prefix":"10.1517","volume":"5","author":[{"given":"Shikha","family":"Nanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2005,3,2]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","volume":"334","author":"BAZZONI F","year":"1996","journal-title":"iN. Engl. J. Med. i"},{"key":"CIT0002","first-page":"771","volume":"2","author":"FELDMANN M","year":"2001","journal-title":"iNat. Immune]. i"},{"key":"CIT0004","first-page":"356","volume":"423","author":"FIRESTEIN GS","year":"2003","journal-title":"iNature i"},{"key":"CIT0006","first-page":"1521","volume":"163","author":"CHARLES P","year":"1999","journal-title":"DAVIS D iet al.: i Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. iJ. Immune]. i"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2249.1997.3181214.x","volume":"107","author":"MUSSENER A","year":"1997","journal-title":"iClin. Exp. Immune]. i"},{"key":"CIT0009","first-page":"4025","volume":"10","author":"KEFFER J","year":"1991","journal-title":"CAZLARIS H iet al.: i Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. iEMBO J. i"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14656566.2.1.75","volume":"1","author":"MIKULS TR","year":"2001","journal-title":"iExpert Opin. Pharmacuther: i"},{"key":"CIT0012","first-page":"1548","volume":"151","author":"MOHLER KM","year":"1993","journal-title":"SMITH CA iet al.: i Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. iJ. Immune]. i"},{"key":"CIT0014","first-page":"161","volume":"34","author":"KORTH-BRADLEY JM","year":"2000","journal-title":"iAnn. Pharmacuther. i"},{"key":"CIT0015","first-page":"929","volume":"351","author":"ABRAHAM E","year":"1998","journal-title":"GUTIERREZ G iet al.: i Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. iLancet i"},{"key":"CIT0016","first-page":"1697","volume":"334","author":"FISHER CJ Jr, AGOSTI JM,","year":"1996","journal-title":"OPAL SM iet al.: i Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. iN Engl. J. Med. i"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00003246-199609000-00002","volume":"24","author":"COHEN J","year":"1996","journal-title":"iGrit. Care Med. i"},{"key":"CIT0018","first-page":"934","volume":"273","author":"ABRAHAM E","year":"1995","journal-title":"SILVERMAN H iet al.: i Efficacy and safety of monoclonal-antibody to human tumor-necrosis-factor-alpha in patients with sepsis syndrome - a randomized, controlled, double-blind, multicenter clinical-trial. iJAMA i"},{"key":"CIT0019","first-page":"1586","volume":"343","author":"BATHON JM","year":"2000","journal-title":"i A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. iN Engl. J. Med. i"},{"key":"CIT0023","first-page":"478","volume":"130","author":"MORELAND LW","year":"1999","journal-title":"i Etanercept therapy in rheumatoid arthritis. A randomized, controlled itrial. Ann. Intern. Med. i"},{"key":"CIT0024","first-page":"253","volume":"340","author":"WEINBLATT ME","year":"1999","journal-title":"BANKHURST AD iet al.: i A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. iN Engl. J. Med. i"},{"key":"CIT0026","first-page":"706","volume":"14","author":"SHARP JT","year":"1971","journal-title":"Correlation of radiologic, clinical and laboratory abnormalities. iArthritis Rheum. i"},{"key":"CIT0027","first-page":"26","volume":"35","author":"VAN DER HEIJDE DM, VAN LEEUWEN MA,","year":"1992","journal-title":"iArthritic Rheum. i"},{"key":"CIT0028","first-page":"1443","volume":"46","author":"GENOVESE MC","year":"2002","journal-title":"MARTIN RW iet al.: i Etanercept versus methotrexate in patients with early rheumatoid arthritis - two-year radiographic and clinical outcomes. iArthritic Rheum. i"},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"KLARESKOG L","year":"2004","journal-title":"Lancet i"},{"key":"CIT0030","first-page":"763","volume":"342","author":"LOVELL DJ","year":"2000","journal-title":"REIFF A iet al.: i Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. iN Engl. J. Med. i"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"GIANNINI EH","year":"1997","journal-title":"iArthritis Rheum. i"},{"key":"CIT0033","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/14712598.3.1.169","volume":"3","author":"ANANDARAJAH AP","year":"2003","journal-title":"iExpert Opin. Biol. The]: i"},{"key":"CIT0034","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1358\/dot.1999.35.12.564038","volume":"12","author":"ASADULLAH K","year":"1999","journal-title":"iDrugs Today i"},{"key":"CIT0035","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"GORMAN JD","year":"2002","journal-title":"iNew Engl. J. Med. i"},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jir.1998.18.219","volume":"18","author":"CREW MD","year":"1998","journal-title":"iJ. Interferon Cytokine Res. i"},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"MEASE PJ","year":"2000","journal-title":"Lancet i"},{"key":"CIT0041","first-page":"2014","volume":"349","author":"LEONARDI CL","year":"2003","journal-title":"MATHESON RT iet al.: i Etanercept as monotherapy in patients with psoriasis. iNew Engl. J. Med. i"},{"key":"CIT0042","first-page":"3230","volume":"48","author":"DAVIS JC","year":"2003","journal-title":"J iet al.: i Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - a randomized, controlled trial. iArthritic Rheum. i"},{"key":"CIT0043","first-page":"537","volume":"35","author":"FELDMAN AM","year":"2000","journal-title":"WAGNER D iet al.: i The role of tumor necrosis factor in the pathophysiology of heart failure. iJ. Am. Coll. Cardiol i"},{"key":"CIT0044","first-page":"561","volume":"72","author":"MATSUMORI A","year":"1994","journal-title":"iBr. Heart J. i"},{"key":"CIT0045","first-page":"627","volume":"81","author":"KUBOTA T","year":"1997","journal-title":"FRYE CS iet al.: i Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. iCirc. Res. i"},{"key":"CIT0046","first-page":"1044","volume":"103","author":"BOZKURT B","year":"2001","journal-title":"WARREN MS iet al.: i Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. iCirculation i"},{"key":"CIT0047","first-page":"123","volume":"86","author":"ANKER SD COATS AJS","year":"2002","journal-title":"iInt. I Cardiol i"},{"key":"CIT0049","first-page":"807","volume":"138","author":"KWON HJ","year":"2003","journal-title":"iAnn. Intern. Med. i"},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","volume":"43","author":"NORONHA IL","year":"1993","journal-title":"iKidney Int. i"},{"key":"CIT0051","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","volume":"44","author":"STONE JH","year":"2001","journal-title":"iArthritis Rheum. i"},{"key":"CIT0053","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2796.2002.01067.x","volume":"252","author":"ARDIZZONE S","year":"2002","journal-title":"iIntern. Med. i"},{"key":"CIT0054","first-page":"1301","volume":"3","author":"GANESAN S","year":"2002","journal-title":"iCarr: Opin. Investig. Drugs i"},{"key":"CIT0058","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","volume":"44","author":"REIFF A","year":"2001","journal-title":"iArthritis Rheum. i"},{"key":"CIT0062","first-page":"417","volume":"191","author":"FAYYAZI A","year":"2000","journal-title":"SORURI A iet al.: i Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. iPathol i"},{"key":"CIT0064","first-page":"5022","volume":"157","author":"SENALDI G","year":"1996","journal-title":"I iImmunol i"},{"key":"CIT0065","first-page":"3504","volume":"162","author":"BEAN AGD, ROACH DR,","year":"1999","journal-title":"BRISCOE H iet al.: i Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. I iImmunol i"},{"key":"CIT0066","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"KEANE J","year":"2001","journal-title":"iN Engl. J. Med. i"},{"key":"CIT0072","first-page":"S154","volume":"44","author":"WALLIS WJ","year":"2001","journal-title":"HOLMDAHL R iet al.: i Infection reports with etanercept (Enbrel) therapy. iArthritis Rheum. i"},{"key":"CIT0075","unstructured":"Abbott Laboratories: Humira\u00ae (Adalimumab) package insert. Abbott Laboratories, North Chicago (IL), USA (2003)."},{"key":"CIT0076","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","volume":"48","author":"SLIFMAN NR","year":"2003","journal-title":"iArthritis Rheum. i"},{"key":"CIT0077","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","volume":"167","author":"WOOD KL","year":"2003","journal-title":"iAm. J. Respir. Crit. Care Med. i"},{"key":"CIT0078","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/art.11242","volume":"48","author":"WOLFE F","year":"2003","journal-title":"iArthritis Rheum. i"},{"key":"CIT0080","first-page":"307","volume":"85","author":"GRIDLEY G","year":"1993","journal-title":"EKBOM A iet al.: i Incidence of Cancer Among Patients with Rheumatoid-Arthritis. iJ. Natl. Cancer Inst. i"},{"key":"CIT0081","first-page":"1753","volume":"32","author":"MELLEMKJAER L","year":"1996","journal-title":"iEar: J. Cancer i"},{"key":"CIT0082","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","volume":"88","author":"THOMAS E","year":"2000","journal-title":"iInt. J. Cancer i"},{"key":"CIT0083","first-page":"963","volume":"48","author":"EKSTROM K","year":"2003","journal-title":"BRANDT L iet al.: i Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. iArthritis Rheum. i"},{"key":"CIT0084","first-page":"180","volume":"317","author":"BAECKLUND E","year":"1998","journal-title":"iBr. Med. J. i"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.5.5.1175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T03:20:46Z","timestamp":1735701646000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.5.5.1175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,3,2]]},"published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1517\/14656566.5.5.1175"],"URL":"https:\/\/doi.org\/10.1517\/14656566.5.5.1175","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}